News
7h
Zacks.com on MSNMDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing RightsMadrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...
11h
Zacks.com on MSNMadrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
8h
Investor's Business Daily on MSNMadrigal Pharmaceuticals Hits 80-Plus Relative Strength Rating BenchmarkMadrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.
1d
InvestorsHub on MSNMadrigal Pharmaceuticals shares surge after extended patent protection for MASH therapyMadrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...
The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...
The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...
Investors in Madrigal Pharmaceuticals Inc (Symbol: MDGL) saw new options become available this week, for the June 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...
Investors in Madrigal Pharmaceuticals Inc (Symbol: MDGL) saw new options become available today, for the January 2025 expiration. One of the key data points that goes into the price an option ...
Read about Madrigal Pharmaceuticals Inc (MDGL:XNAS) stock and today's latest news and financial updates. MDGL - Madrigal Pharmaceuticals Inc News | Morningstar Morningstar brands and products ...
Madrigal Pharmaceuticals, Inc. (MDGL) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results